• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice

    2022-06-07 10:50:12MengLiWuFengLiangLiuJingSunXinLiJianRuQinQiHongYanXiaJinXinWenChenYongTangZhengJinCunZhaoJianHuaWang
    Zoological Research 2022年3期

    Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Jian-Ru Qin, Qi-Hong Yan, Xia Jin, Xin-Wen Chen, Yong-Tang Zheng, Jin-Cun Zhao,*, Jian-Hua Wang,,5,*

    1 College of Life Science, Henan Normal University, Xinxiang, Henan 453007, China

    2 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong 510530, China

    3 Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology,Chinese Academy of Sciences, Kunming, Yunnan 650223, China

    4 State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China

    5 University of Chinese Academy of Sciences, Beijing 100049, China

    ABSTRACT COVID-19 is an immune-mediated inflammatory disease caused by SARS-CoV-2 infection, the combination of anti-inflammatory and antiviral therapy is predicted to provide clinical benefits.We recently demonstrated that mast cells (MCs) are an essential mediator of SARS-CoV-2-initiated hyperinflammation.We also showed that spike protein-induced MC degranulation initiates alveolar epithelial inflammation for barrier disruption and suggested an off-label use of antihistamines as MC stabilizers to block degranulation and consequently suppress inflammation and prevent lung injury.In this study, we emphasized the essential role of MCs in SARS-CoV-2-induced lung lesions in vivo, and demonstrated the benefits of co-administration of antihistamines and antiviral drug remdesivir in SARS-CoV-2-infected mice.Specifically, SARSCoV-2 spike protein-induced MC degranulation resulted in alveolar-capillary injury, while pretreatment of pulmonary microvascular endothelial cells with antihistamines prevented adhesion junction disruption; predictably, the combination of antiviral drug remdesivir with the antihistamine loratadine, a histamine receptor 1 (HR1) antagonist, dampened viral replication and inflammation, thereby greatly reducing lung injury.Our findings emphasize the crucial role of MCs in SARS-CoV-2-induced inflammation and lung injury and provide a feasible combination antiviral and anti-inflammatory therapy for COVID-19 treatment.

    Keywords: SARS-CoV-2; Mast cell; Remdesivir;Antihistamine; Combinational therapy

    INTRODUCTION

    Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infection.This infection dysregulates the immune system by inducing hyperinflammatory responses, which produce excessive pro-inflammatory mediators that trigger acute lung injury, septic shock, acute respiratory distress syndrome, and multiple organ failure, thus contributing to significant morbidity and mortality (Attiq et al., 2021; Chen et al., 2020; Huang et al., 2021; Qin et al., 2020; Song et al., 2020; Tian et al., 2021;Wang et al., 2020a; Xu et al., 2020).To curtail this disease,the US Food and Drug Administration (FDA) has approved and authorized two mRNA-based vaccines (Pfizer-BioNTech,Moderna) and one recombinant adenovirus-26 vaccine(Janssen, Ad26.COV2.S) for population use, while the World Health Organization (WHO) has approved the BBIBP-CorV and CoronaVac inactivated vaccines, both of which were developed in China.Globally more than 100 candidate vaccines, including 20 inactivated SARS-CoV-2 vaccines, are under development (Marfe et al, 2021).

    Considering the limited durability of protection conferred by existing vaccines and the real-life reduction in vaccine effectiveness due to the emergence of SARS-CoV-2 variants,efficacious pharmacological treatment for COVID-19 is still urgently needed.Several drugs repurposed from viral disease treatments have been tested against COVID-19, including remdesivir, favipiravir, and lopinavir/ritonavir, which interfere with the function of SARS-CoV-2 RNA-dependent RNA-polymerases (RdRp) (Biswas et al, 2021).The ribonucleoside analogue molnupiravir (EIDD-2 801, MK-4 482), developed by Merck and Ridgeback, has been approved in the UK for the oral treatment of COVID-19 (Mahase, 2021a;c).Paxlovid (PF-07311332 and ritonavir), another oral-administration candidate developed by Pfizer, is reported to reduce the risk of hospitalization or death by 89% compared to placebo in nonhospitalized high-risk adults with COVID-19 (Mahase, 2021b).Furthermore, the Janus kinase (JAK) 1/2 inhibitor baricitinib has been approved for use in Japan (23 April 2021) (Mouffak et al, 2021) and several monoclonal antibodies (mAbs) are under development for COVID-19 treatment and/or prophylaxis (Mouffak et al, 2021).

    Remdesivir is a nucleotide analogue that can efficiently inhibit viral RdRp, with well-established activity against various flaviviruses (Konkolova et al, 2020).Remdesivir shows efficient repression of SARS-CoV-2 replication in cellular and mouse models (Pruijssers et al, 2020), and shortens recovery time in adult patients following early administration (Beigel et al, 2020; De Clercq, 2021; Rochwerg et al, 2020; Wang et al,2020b, 2020c).Thus, remdesivir (Veklury) has been approved by the US FDA for the treatment of COVID-19 in adults and children older than 12 years (Rubin et al, 2020).

    Many COVID-19 patients manifest symptoms associated with inflammation (Attiq et al, 2021; Daher, 2021), and the combination of anti-inflammatory and antiviral therapy seems to be beneficial (De Clercq, 2021; Mouffak et al, 2021).The combination of remdesivir with corticosteroids(dexamethasone) reduces both viral load and inflammation in hamster models of SARS-CoV-2 infection (Ye et al, 2021),and reduces the 30-day mortality rate from 19.7% to 12.6% in severe COVID-19 patients (Benfield et al, 2021).Remdesivir combined with the JAK 1/2 inhibitor baricitinib is superior to remdesivir alone in shortening recovery time and accelerating clinical improvement, especially in patients receiving high-flow oxygen or noninvasive ventilation, with fewer serious adverse events (Kalil et al, 2021).

    Mast cells (MCs) are tissue-resident cells strategically placed throughout the host-environment interface.In addition to being the main effector cells in allergic response, MCs also play regulatory roles in various pathophysiological processes(Komi et al., 2020; Lam et al., 2021).Postmortem lung biopsies of COVID-19 patients show a massive increase in the density of perivascular and septal MCs (Da Silva Motta Junior et al., 2020; Dos Santos Miggiolaro et al., 2020).SARS-CoV-2 infection is reported to trigger MC infiltration into the pulmonary parenchyma of African green monkeys (Malone et al, 2021).We also recently demonstrated that SARS-CoV-2 triggers rapid degranulation of MCs and initiates alveolar epithelial inflammation and subsequent lung injury in mice (Wu et al, 2021).These studies suggest that MCs may play a critical role in the pathogenesis of SARS-CoV-2 and may be a novel therapeutic cell target for the treatment of COVID-19(Lam et al, 2021; Malone et al, 2021; Murdaca et al, 2021).Indeed, we previously found that administration of clinically approved MC stabilizers (i.e., antihistamines ebastine and loratadine) dampens SARS-CoV-2-induced production of proinflammatory factors and prevents lung injury in mice (Wu et al, 2021).In this study, we revealed the essential role of MCs in SARS-CoV-2-induced lung injury.Notably, we investigated the potential benefits of suppressing viral replication and alleviating hyperinflammation by co-administration of antihistamines and remdesivir in a mouse model of SARSCoV-2 infection.

    MATERIALS AND METHODS

    Ethics statement

    All animal experiments were approved by the Institutional Animal Care and Use Committee of the Guangzhou Institutes of Biomedicine, Chinese Academy of Sciences (Approval No.N2021016).All SARS-CoV-2 animal model experiments and protocols were discussed extensively with biosafety officers and facility managers.All animal and viral experiments were conducted within an animal biosafety level 3 (ABSL-3) facility.

    Cells

    Human MCs (LAD2) were cultured in RPMI 1640 medium(Gibco, USA) containing 10% fetal bovine serum (FBS)(Gibco, USA) with 100 U/mL penicillin and 100 μg/mL streptomycin.For degranulation, the LAD2 cells were grown in StemPro-34 medium (Gibco, USA) supplemented with 100 μg/mL stem cell factor (Novoprotein, China), 10 μg/mL interleukin-6 (IL-6) (Novoprotein, China), nutrient supplement(NS) (Gibco, USA), 100 U/mL penicillin (Invitrogen, USA),100 μg/mL of streptomycin (Invitrogen, USA), and 2 mmol/L L-glutamine (Gibco, USA).Human lung microvascularendothelial cells (HULEC-5a) were cultured in MCDB131 medium (Gibco, USA) containing 10 ng/mL epidermal growth factor (EGF) (R&D, USA), 1 μg/mL hydrocortisone (Apexbio,China), 10 mmol/L L-glutamine (Gibco, USA), 10% FBS(Gibco, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin.

    Mast cell degranulation

    The LAD2 cells (3×105) were exposed to recombinant receptor-binding domain (RBD) derived from wild-type SARSCoV-2 (GenScript, Z03483, China) or the 501Y.V2 variant(GenScript, Z03531, China) for indicated times.The cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, USA) at room temperature (RT) for 30 min, then washed three times with phosphate-buffered saline (PBS), and incubated with antiavidin-FITC (500 ng/mL, Invitrogen, A821, USA) diluted in permeabilized buffer (1% FBS and 0.2% Triton X-100 in PBS)for 1 h at 4 °C.After washing, cells were detected with flow cytometry (BD Accuri C6, USA) and analyzed with FlowJo v7.6.1 (USA).Histamine in the LAD2 cell culture supernatants was quantified with an enzyme-linked immunosorbent assay(ELISA) kit according to the manufacturer’s instructions(Sangon Biotech, D751012, China).Compound 48/80(C48/80) (4 μg/mL) (Sigma, C2313, USA), which can stimulate MC degranulation, was used as the control.All experiments were performed at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    Mouse infection

    Specific pathogen-free 6-week-old female wild-type BALB/c mice were infected intranasally with the 501Y.V2 SARS-CoV-2 variant (B.1.351, GISAID: EPI_ISL_2423556) at a 50% cell culture infective dose (CCID50) of 7.1×104.The 501Y.V2 strain was provided by Guangzhou Medical University,Guangdong, China.Loratadine (Lor.) (10 mg/kg) (Sigma-Aldrich, USA) was administered intraperitoneally (i.p.) 1 day before infection and Lor.treatment was continued each day over the course of infection; remdesivir (25 mg/kg) was administered (i.p.) at the time of infection and used once daily until euthanasia.Five mice in each group and three mice in control group.The lungs were collected at 3 days postinfection (dpi) for pathological, virological, and immunological analyses.Experiments were performed in the ABSL-3 facility at the First Affiliated Hospital of Guangzhou Medical University.

    Pathology

    The lungs of mice were harvested and fixed in zinc formalin.For routine histology, tissue sections (~4 μm each) were stained with hematoxylin and eosin (H&E) or toluidine blue.In brief, the tissue sections were stained with 1% toluidine blue(Sigma-Aldrich, USA) for 1 h at RT, then washed in distilled water three times, anhydrous ethanol two times, and covered with a coverslip.Pathological score was assessed according to the degree of lung tissue lesions, including alveolar septal thickening, hemorrhage, inflammatory cell infiltration, and consolidation.Semi-quantitative assessment was determined as follows: 0: No alveolar septal thickening; 1: Very mild alveolar septal thickening, with area of alveolar septal thickening, hemorrhage, and inflammatory cell infiltration<10%; 2: Mild alveolar septal thickening, with area of alveolar septal thickening, hemorrhage, and inflammatory cell infiltration 10%-25%; 3: Moderate alveolar septal thickening,with area of alveolar septal thickening, hemorrhage,inflammatory cell infiltration, mucosa desquamation, and fibrinous exudate 25%-50%; 4: Marked alveolar septal thickening, with area of alveolar septal thickening,hemorrhage, inflammatory cell infiltration, mucosa desquamation, and fibrinous exudate 50%-75%; 5: Very marked alveolar septal thickening, with area of alveolar septal thickening, hemorrhage, inflammatory cell infiltration, mucosa desquamation, and fibrinous exudate >75%.

    For immunofluorescence, frozen lung sections were blocked with 5% bovine serum albumin (BSA) in PBS at RT for 1 h,incubated with anti-VE-cadherin primary antibodies (Abcam,ab205336, UK) for 2 h at RT, then incubated with Alexa Flour 488-labeled goat anti-rabbit IgG (Invitrogen, A11034, USA) for 1 h at RT.The sections were further incubated with DAPI(Beyotime, China) and analyzed using a Pannoramic MIDI slice scanning apparatus (3DHISTECH, USA).The fixed tissue sections were stained at the Pathology Center of the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    Flow cytometry and fluorescence microscopy

    To detect VE-cadherin expression using flow cytometry,HULEC-5a cells (1×105) were treated with RBD proteins(2 μg/mL) derived from wild-type SARS-CoV-2 (GenScript,Z03483, China) and co-cultured with LAD2 cells (1×105) in the presence or absence of RBD proteins (2 μg/mL) or stimulated with RBD-treated LAD2 cell culture supernatants (300 μL) for 48 h at 37 °C.Medium treatment was used as the control.In other groups (3 repeats), Lor.(2.5 μg/mL, Selleck,China),ebastine (Eba., 1.5 μg/mL, Selleck, China), or ketotifen fumarate (Ket., 4 μg/mL, Yuanye Biology, S46226, China) was used to pretreat HULEC-5a cells for 2 h before stimulation.The cells were harvested and blocked with 5% BSA for 1 h at RT, incubated with anti-VE-cadherin antibodies (Cell Signaling Technology, D87F2, USA) for 2 h at RT, washed with FACS buffer, incubated with Alexa Flour 488-labeled goat anti-rabbit(Invitrogen, A11034, USA) for 30 min at RT, then analyzed using flow cytometry.The HULEC-5a cells were also seeded on a coverslip to form a monolayer to observe VE-cadherin fluorescence using an Olympus CKX53 fluorescence microscope (Japan).

    To detect IL-6 expression at the protein level, HULEC-5a cells (3×105) were treated with LAD2 culture supernatant(250 μL) for 24 h at 37 °C, then harvested, mixed with a leukocyte activation cocktail containing BD GolgiPlug (BD,550583, USA), and cultured for 6 h at 37 °C.Following activation, cells were washed with FACS buffer.The BD Cytofix/Cytoperm solution (BD, 554722, USA) was used for the simultaneous fixation and permeabilization of cells for 20 min at 4 °C before intracellular cytokine staining.Rat antihuman IL-6-PE (BD, MQ2-6A3, USA) was added, and the cells were further incubated at 4 °C overnight.After washing,the cells were resuspended in FACS buffer, then analyzed using flow cytometry (BD Accuri C6, USA) and FlowJo v7.6.1(USA).In other groups (3 repeats), Lor.(2.5 μg/mL, Selleck,China), Eba.(1.5 μg/mL, Selleck, China), or Ket.(4 μg/mL,Yuanye Biology, S46226, China) was used to pretreat HULEC-5a cells for 2 h at 37 °C before stimulation with the LAD2 culture supernatant.All experiments were performed at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    Real-time polymerase chain reaction (RT-PCR)

    Total RNA from cells/tissues was extracted using TRIzol Reagent (Invitrogen, USA), then reverse transcribed into cDNA using a synthesis kit (TOYOBO, FSQ-301, Japan)according to the manufacturer’s instructions.RT-PCR was carried out using SYBR qPCR Mix (GeneSTAR, A33-101,China) with the following thermal cycling conditions: initial denaturation at 95 °C for 2 min, amplification with 40 cycles of denaturation at 95 °C for 15 s, primer annealing at 60 °C for 15 s, and extension at 72 °C for 30 s.The data were analyzed by SYBR green-based semi-quantification and normalized withGAPDH.RT-PCR was performed on the Bio-Rad CFX96 Real-Time PCR system (USA).Mouse-extracted RNA was used to measure copies of the SARS-CoV-2 nucleocapsid gene using a THUNDERBIRD Probe One-step qRT-PCR Kit(TOYOBO, Japan).The standard samples were provided by Dr.Ling Chen (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China).The primers and probes used for RT-PCR are listed in Supplementary Table S1.Mouse tissue RNA was isolated in the ABSL-3 facility at the First Affiliated Hospital of Guangzhou Medical University, and RT-PCR was performed at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences.

    RNA sequencing (RNA-seq) and data analysis

    The HULEC-5a cells were cultured with RBD-treated LAD2 cell culture supernatants for 24 h at 37 °C.Total RNA was extracted using TRIzol (Invitrogen,USA) according to the manufacturer’s protocols, and ribosomal RNA was removed using a QIAseq FastSelect-rRNA HMR Kit (Qiagen,Germany).Fragmented RNA (average length ~200 bp) was subjected to first- and second-strand cDNA synthesis,followed by adaptor ligation and enrichment under a low cycle according to the instructions provided with the NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs,USA).The purified library products were evaluated using Agilent 2200 TapeStation and Qubit v2.0 (Life Technologies,USA).The libraries were paired-end sequenced (PE150,sequencing reads 150 bp) at Genewiz (China) using the Illumina HiSeq 3000 platform.

    Raw RNA-seq reads were filtered using Trimmomatic v0.36.The filtered reads were mapped to the human (hg38)reference genome using HISAT v2.1 and corresponding gene annotations (GRCh38.p13) with default settings.Total counts per mapped gene were determined using the FeatureCounts function in the SubReads package v1.5.3 with default parameters.The counts matrix was then obtained using the feature counts as input for differential gene expression analysis with the Bioconductor package DESeq2 v1.26 in R v4.0.Gene counts with more than five reads in a single sample or more than 50 total reads across all samples were retained for further analysis.The filtered counts matrix was normalized using the DESeq2 method to remove libraryspecific artifacts.Principal component analysis was based on global transcriptome data using the build-in function prcomp in R.Genes with a log2 fold-change>1 or <-1 and adjustedP<0.05 (Benjamini-Hochberg corrected) were considered significant.Transcription factor and functional enrichment analyses were performed using Metascape (Zhou et al, 2019)(https://metascape.org/gp/index.html#/main/step1).Gene set enrichment analysis (GSEA) was conducted using the R package clusterProfiler v3.18.1.

    Statistical analysis

    GraphPad Prism v8.0 was used for statistical analysis.For direct intragroup comparison, student’s unpaired two-tailedttest was performed to analyze significant differences.For comparisons among multiple groups, one-way analysis of variance (ANOVA) was performed.Significance levels were determined at*:P<0.05;**:P<0.01;***:P<0.001.

    RESULTS

    Spike-induced MC degranulation predisposes microvascular endothelial cells to damage

    We previously demonstrated that SARS-CoV-2 spike/RBD protein-induced MC degranulation initiates alveolar epithelial inflammation and barrier disruption in mice (Wu et al, 2021).To investigate whether the presence of MCs or their degranulation induces alveolar-capillary injury, HULEC-5a cells were seeded on a coverslip to form a cell monolayer,then treated with spike/RBD-stimulated LAD2 cell culture supernatant (Deg.Supern.) for 48 h.The adherent junction protein VE-cadherin in the HULEC-5a cells was examined as an indicator of microvascular endothelial barrier integrity(Wang et al, 2020a).Results showed that Deg.Supern.markedly altered VE-cadherin organization in the HULEC-5a cells (Figure 1A).Direct stimulation with spike/RBD for 48 h or co-culture with LAD2 cells did not disrupt VE-cadherin;however, the addition of spike/RBD to the co-culture of LAD2/HULEC-5a cells (LAD2/RBD) altered VE-cadherin organization (Figure 1B).

    Histamine receptor 1 (HR1) antagonists (i.e., Ket., Eba., and Lor.) are routinely used to treat allergies in humans (Slater et al, 1999).In addition to their primary mechanism of antagonizing histamine at HR1, they may also act on other mediators of allergic reactions (Abdelaziz et al, 2000; Slater et al, 1999).Thus, we next investigated whether these antihistamines could provide protection against MC degranulation-induced disruption of adhesion junctions.HULEC-5a cell monolayers were first pretreated with the antihistamines, then co-cultured with LAD2 cells in the presence of the spike/RBD protein or directly treated with the spike/RBD-stimulated LAD2 cell culture supernatant.Results showed that pretreatment with the antihistamines rescued MC degranulation-triggered disruption of VE-cadherin (Figure 1C).

    The MC degranulation-induced disruption of VE-cadherin in the HULEC-5a cells was quantified using flow cytometry.Results showed that treatment with the spike/RBD-stimulated LAD2 cell culture supernatant (Deg.Supern.) (Figure 1D) orco-culture with LAD2 cells in the presence of the spike/RBD protein (LAD2/RBD) (Figure 1E) decreased VE-cadherin expression.However, pretreatment of the HULEC-5a cells with the antihistamines rescued VE-cadherin impairment(Figure 1D, E).

    Figure 1 MC degranulation disrupts VE-cadherin in HULEC-5a cells

    We previously showed that SARS-CoV-2 spike/RBD triggers MCs to release cellular mediators (Wu et al, 2021).Here, the spike/RBD-induced rapid degranulation of MCs was confirmed by assessing the reduction in immunostaining intensity of cytoplasmic avidin particles (Figure 1F), and histamine released in the cell culture supernatants was quantified (Figure 1G).

    Taken together, these results demonstrate that spike/RBD-triggered MC degranulation predisposes microvascular endothelial cells to damage.

    Pretreatment of microvascular endothelial cells with antihistamines abolishes MC degranulation-induced inflammation

    We next performed transcriptome analysis to examine inflammation in microvascular endothelial cells induced by MCdegranulation.The culture supernatants of spike/RBD-treated LAD2 cells were used to treat HULEC-5a cells for 24 h, after which the cell transcriptomes were analyzed using standard protocols.Data from five independent repeats were analyzed.As shown in the volcano plot, a total of 1 641 up-regulated genes and 835 down-regulated genes were identified in the HULEC-5a cells after treatment with the spike/RBD-treated LAD2 cell supernatant (Figure 2A).Gene Ontology (GO)functional enrichment analysis of differentially expressed genes (DEGs) showed obvious up-regulation of gene sets involved in cytokine signaling/production and inflammation regulation (Figure 2B).GSEA linked the up-regulated genes to inflammatory response regulation (Figure 2C).The core DEGs involved in the regulation of inflammation were catalogized,with significant enrichment in pro-inflammatory cytokine/chemokine-encoding genes, particularly S100 calcium binding protein A9 (S100A9), C-X-C motif chemokine ligand 11(CXCL11), C-C motif chemokine ligand 7 (CCL7), CX-C motif chemokine 10 (CXCL10),IL-6, and intercellular cell adhesion molecule-1 (ICAM-1) (Figure 2D).The expression levels of these significantly up-regulated cytokine/chemokineencoding genes were confirmed using qRT-PCR (Figure 2E).Notably, pretreatment of the HULEC-5a cells with Ket., Eba.,or Lor.significantly reduced MC degranulation-induced expression of these pro-inflammatory cytokines/chemokines(Figure 2E).IL-6 expression at the protein level was detected by intracellular immunostaining and flow cytometry, which confirmed the above findings (Figure 2F, G).Taken together,these results indicate that spike/RBD-triggered MC degranulation significantly induces inflammation in human microvascular endothelial cells, and pretreatment of cells with antihistamines abolishes the subsequent induction of inflammatory factors.

    Combination of remdesivir and antihistamine reduces SARS-CoV-2 replication and inflammation and protects lung injury

    We next investigated whether the co-administration of remdesivir and antihistamines can repress SARS-CoV-2 replication and alleviate inflammation.The 501Y.V2 strain of SARS-CoV-2 was used to infect wild-type BALB/c mice (Shuai et al, 2021).The spike/RBD of this variant triggered MC activation for rapid degranulation with dose-dependent effects(Supplementary Figure S1).

    The BALB/c mice were treated with the antihistamine Lor.(10 mg/kg; i.p.) 1 day prior to intranasal infection with the 501Y.V2 variant (7.1×104CCID50), then administered Lor.once daily until the mice were euthanized at 3 dpi.Remdesivir(25 mg/kg) was administered (i.p.) at the point of infection and used once daily until euthanasia (Figure 3A).

    Compared with the infection group, the administration of Lor.and/or remdesivir did not further accelerate weight loss in mice (Figure 3B).As expected, the administration of remdesivir resulted in a 10-fold decrease in the SARS-CoV-2 viral load in the lung (Figure 3C).While administration of Lor.alone did not markedly suppress viral load (Figure 3C) (Wu et al, 2021), it significantly reduced the production of proinflammatory cytokines/chemokines, such asIL-6, tumor necrosis factor α (TNF-α), C-C motif chemokine ligand 5(CCL5),CXCL11, C-C motif chemokine ligand 20 (CCL20),andICAM-1(Figure 3D).Interestingly, while remdesivir showed incomplete inhibition of pro-inflammatory factor production, co-administration of Lor.and remdesivir greatly reduced pro-inflammatory factors to similar basal levels detected in the mock-infected controls (Figure 3D).

    Frozen lung sections were immunostained for VE-cadherin to visualize pulmonary microvascular integrity (Wang et al,2020a).SARS-CoV-2 infection disrupted the integrity,remdesivir alone maintained integrity to some extent, but completely preserved integrity when combined with Lor.(Figure 3E).

    Mouse lung pathology was analyzed by H&E staining.Lung lesions, including alveolar septal thickening, inflammatory cell infiltration, mucosa desquamation, hyperemia, and hemorrhage, were observed in the SARS-CoV-2-infected mice(Figure 4A).Remdesivir administration reduced lung lesions,although damage still occurred.Notably, administration of Lor.or remdesivir/Lor.in combination greatly reduced lung lesions(Figure 4A).Pathological scores were assessed according to the degree of lung lesions in the tissue sections (Figure 4B).MCs and degranulation were indicated by metachromatic labeling with toluidine blue (Wu et al, 2021).SARS-CoV-2-induced peribronchial accumulation of MCs was observed and granule release was detected in the alveolar space(Figure 5B).Administration with remdesivir alone did not reduce MC accumulation or degranulation (Figure 5B).However, as observed previously (Wu et al, 2021), no MC accumulation or degranulation was observed in the Lor.or combined remdesivir/Lor.groups (Figure 5C-E).

    Figure 2 MC degranulation induces inflammation in human microvascular endothelial cells

    Figure 3 Combined remdesivir and Lor.treatment dampens SARS-CoV-2 replication and inflammation

    Figure 4 Combined remdesivir and Lor.treatment reduces lung lesions in SARS-CoV-2-infected mice

    Figure 5 Administration of Lor.or Lor./remdesivir blocks MC accumulation

    Taken together, these results suggest that co-administration of remdesivir and antihistamines reduces viral replication and inhibits inflammation, thereby preventing lung damage.

    DISCUSSION

    Various therapeutic combinations have been trialed for the treatment of COVID-19, several of which have shown clinical improvement.For example, the addition of minocycline to favipiravir treatment significantly reduces pro-inflammatory cytokines IL-6 and IL-8 in COVID-19 patients (Itoh et al, 2022).The combination of the anti-inflammatory JAK1/2 inhibitor ruxolitinib and anti-C5a complement mAb eculizumab significantly decreases circulating D-dimer levels, reduces pulmonary lesions, and improves respiratory symptoms in severe COVID-19 patients (Giudice et al, 2020).Combined treatment of molnupiravir and favipiravir potentiates antiviral efficacy in SARS-CoV-2-infected hamsters (Abdelnabi et al,2021).Triple antiviral therapy with interferon beta-1b,lopinavir-ritonavir, and ribavirin is superior to lopinavir/ritonavir alone in shortening viral shedding, alleviating disease symptoms, and facilitating recovery in patients with mild to moderate COVID-19 (Hung et al, 2020).In addition, two mAb combinations (casirivimab/imdevimab and bamlanivimab/etesevimab) have been authorized by the US FDA for emergency use to treat non-hospitalized COVID-19 patients with mild to moderate disease but at risk for clinical deterioration (Mouffak et al, 2021).

    As the first antiviral drug formally approved for the treatmentof COVID-19, remdesivir is a priority for developing drug combination.However, treatments used in combination with remdesivir are not limited to anti-inflammatory agents.For example, remdesivir with convalescent plasma shows clinical improvement in severe COVID-19 patients with X-linked agammaglobulinemia (Iaboni et al, 2021).Remdesivir shows synergistic effects at reducing viral replication in cell culture models when used in combination with the antifungal itraconazole (Schloer et al, 2021), antidepressant fluoxetine(Schloer et al, 2021), folate antagonist methotrexate(Stegmann et al, 2021), and Zn-ejector drugs disulfiram or ebselen (Chen et al, 2021).The combination of remdesivir and human soluble ACE2 also displays a strong additive effect on viral replication inhibition (Monteil et al, 2021).

    When remdesivir is used in combination with antiinflammatory agents, one crucial question is the timing for the administration of both components.Early administration of remdesivir shortens the time to clinical improvement in adult COVID-19 patients, but the benefit decreases or disappears when administered at the late phase of infection (Beigel et al,2020; De Clercq, 2021; Rochwerg et al, 2020; Wang et al,2020b), indicating that remdesivir should be administered as early as possible.Here, although remdesivir application at the time of infection significantly reduced pulmonary viral load and lung lesions in mice, it did not completely block the production of pro-inflammatory mediators and thus did not provide full protection against injury.It is possible that drug-inactivated viruses or viral components can still induce rapid inflammationand sequential immune cascades, causing tissue injury (Rauti et al, 2021).Thus, anti-inflammatory agents should also be applied as early as possible before the onset of the inflammatory response.Inadequate blockade of inflammation may account for the lack of clinical benefit found when tocilizumab or corticosteroids are combined with remdesivir(Garibaldi et al, 2021; Rosas et al, 2021).In our study, early combined treatment with the antihistamine loratadine and remdesivir showed complete repression of pro-inflammatory mediator production in infected mice, highlighting the need for early administration of anti-inflammatory agents.

    Growing evidence suggests that MCs play critical roles in the pathogenesis of SARS-CoV-2 (Lam et al, 2021; Malone et al, 2021; Murdaca et al, 2021).We recently found that SARSCoV-2-induced MC degranulation initiates alveolar epithelial inflammation and causes lung lesions in ACE2-humanized mice (Wu et al, 2021).MCs have also been proposed as novel therapeutic cellular targets for the treatment of COVID-19(Lam et al, 2021; Malone et al, 2021; Murdaca et al, 2021).Repurposed famotidine, a histamine-2 receptor (HR2)antagonist, significantly improves pulmonary symptoms in COVID-19 patients (Freedberg et al, 2020; Janowitz et al,2020; Malone et al, 2021).Famotidine has also been shown to inhibit Toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection (Mukherjee et al, 2021).Administration of famotidine in combination with the HR1 antagonist cetirizine has also been shown to reduce mortality in COVID-19 patients(Hogan Ii et al, 2020; Mather et al, 2020).We previously demonstrated that the antihistamines ebastine and loratadine,as MC stabilizers blocking degranulation, can dampen SARSCoV-2-induced production of pro-inflammatory factors, thereby preventing lung injury in mice (Wu et al, 2021).In this study,these HR1 antagonists were used to pre-block microvascular endothelial cells, resulting in significant repression of inflammatory mediator production in target cells.Importantly,co-administration of loratadine with remdesivir dampened both SARS-CoV-2 replication and inflammation and protected mice from lung injury.

    Taken together, our results emphasize the critical role of MCs in the pathogenesis of SARS-CoV-2 and demonstrate the versatile benefit of antihistamine and remdesivir coadministration in suppressing viral replication and alleviating inflammation in a mouse model of SARS-CoV-2 infection.Our findings provide a feasible approach to combine antiviral and anti-inflammatory agents for COVID-19 treatment.Thus, the clinical benefits warrant further investigation.

    DATA AVAILABILITY

    All raw RNA-seq data used in this study have been deposited at the National Genomics Data Center (BioProjectID PRJCA007111, https://bigd.big.ac.cn/gsa-human/browse/HRA001517), Science Data Bank (Data doi:10.11922/sciencedb.01655, https://www.scidb.cn/s/MBb6r2), and NCBI(BioProjectID PRJNA822440, http://www.ncbi.nlm.nih.gov/bioproject/822440).

    SUPPLEMENTARY DATA

    Supplementary data to this article can be found online.

    COMPETING INTERESTS

    The authors declare that they have no competing interests.

    AUTHORS’ CONTRIBUTIONS

    Conceptualization: J.H.W.; Data Curation and Visualization:M.L.W., F.L.L., J.S., and X.L.Formal Analysis: M.L.W.and J.H.W.; Resources: J.H.W., J.C.Z., J.S., J.R.Q., X.J., Y.T.Z.,and X.W.C.; Software: Q.H.Y.; Writing-Original Draft: M.L.W.and J.H.W.; Writing-Review & Editing: X.J.and J.H.W.; Project Administration: J.H.W., J.C.Z., and Y.T.Z.; Supervision: J.H.W.All authors read and approved the final version of the manuscript.

    ACKNOWLEDGEMENTS

    We thank Prof.Ling Chen for reagents.

    中文字幕熟女人妻在线| 一级毛片aaaaaa免费看小| 亚洲精品成人久久久久久| 欧美另类亚洲清纯唯美| 国产av不卡久久| 日本 av在线| 精品一区二区三区人妻视频| 久久久午夜欧美精品| 白带黄色成豆腐渣| 欧美不卡视频在线免费观看| 亚洲精品日韩av片在线观看| 九色成人免费人妻av| 99久久精品国产国产毛片| 亚洲第一电影网av| 全区人妻精品视频| 国产亚洲91精品色在线| 噜噜噜噜噜久久久久久91| 麻豆国产av国片精品| av女优亚洲男人天堂| 国产乱人偷精品视频| 久久精品国产亚洲av涩爱 | 亚洲国产精品合色在线| 亚洲美女黄片视频| 精品免费久久久久久久清纯| 国产69精品久久久久777片| 少妇的逼水好多| 12—13女人毛片做爰片一| 免费不卡的大黄色大毛片视频在线观看 | 99热这里只有是精品在线观看| 欧美潮喷喷水| 天天躁夜夜躁狠狠久久av| 欧美精品国产亚洲| 久久国内精品自在自线图片| 免费观看精品视频网站| 嫩草影视91久久| 国产国拍精品亚洲av在线观看| 午夜福利视频1000在线观看| 日本一本二区三区精品| 欧美区成人在线视频| 国产伦精品一区二区三区视频9| 日本a在线网址| 久久精品国产99精品国产亚洲性色| 久久亚洲国产成人精品v| 又粗又爽又猛毛片免费看| 亚洲熟妇熟女久久| 一级黄片播放器| 小蜜桃在线观看免费完整版高清| 亚洲精品一区av在线观看| 综合色av麻豆| 成人二区视频| av天堂中文字幕网| 亚洲欧美成人综合另类久久久 | 亚洲精品国产成人久久av| 别揉我奶头~嗯~啊~动态视频| 精品国内亚洲2022精品成人| 日日啪夜夜撸| 一级毛片久久久久久久久女| 色视频www国产| av在线亚洲专区| 最好的美女福利视频网| 综合色丁香网| 国产v大片淫在线免费观看| 精品少妇黑人巨大在线播放 | 午夜福利高清视频| 黄色视频,在线免费观看| 99热全是精品| 免费看光身美女| 五月伊人婷婷丁香| 插阴视频在线观看视频| 99精品在免费线老司机午夜| 国产精品福利在线免费观看| 卡戴珊不雅视频在线播放| 午夜精品国产一区二区电影 | 国产av麻豆久久久久久久| 国产高清三级在线| 日韩欧美在线乱码| 黄色配什么色好看| 身体一侧抽搐| 一a级毛片在线观看| 色综合站精品国产| 性欧美人与动物交配| 国产免费男女视频| 久久99热这里只有精品18| 一边摸一边抽搐一进一小说| 久久久a久久爽久久v久久| 欧美日韩一区二区视频在线观看视频在线 | 国产熟女欧美一区二区| 色哟哟哟哟哟哟| 精品人妻熟女av久视频| 国产麻豆成人av免费视频| 欧美色欧美亚洲另类二区| 成年女人毛片免费观看观看9| 国产在线精品亚洲第一网站| 小蜜桃在线观看免费完整版高清| 亚洲专区国产一区二区| 蜜臀久久99精品久久宅男| 嫩草影院精品99| 日本黄色片子视频| 久久久久国产精品人妻aⅴ院| 国产一区二区在线观看日韩| 高清毛片免费观看视频网站| 国产91av在线免费观看| 国产精品永久免费网站| 欧美精品国产亚洲| 亚洲性夜色夜夜综合| 国产精品女同一区二区软件| 一进一出抽搐动态| 欧美国产日韩亚洲一区| 成人欧美大片| 一个人看视频在线观看www免费| 插逼视频在线观看| 91久久精品电影网| 精品国产三级普通话版| 国产一区二区三区在线臀色熟女| 中国美女看黄片| 亚洲av不卡在线观看| 国产在线精品亚洲第一网站| 2021天堂中文幕一二区在线观| 日本爱情动作片www.在线观看 | 国产爱豆传媒在线观看| 搡老妇女老女人老熟妇| 国产大屁股一区二区在线视频| 欧美三级亚洲精品| 国产一区二区三区在线臀色熟女| 如何舔出高潮| 亚洲一区二区三区色噜噜| 国产一区二区在线av高清观看| 久久久色成人| 91狼人影院| 人人妻人人澡欧美一区二区| 久久久久国内视频| av专区在线播放| 午夜福利18| 丝袜美腿在线中文| 美女被艹到高潮喷水动态| av天堂在线播放| 99国产精品一区二区蜜桃av| 国产欧美日韩精品一区二区| 国产一区二区在线观看日韩| 亚洲欧美中文字幕日韩二区| 国产成人一区二区在线| 亚州av有码| 最近的中文字幕免费完整| 精品少妇黑人巨大在线播放 | 美女大奶头视频| 男女视频在线观看网站免费| 午夜日韩欧美国产| 丰满的人妻完整版| 精品无人区乱码1区二区| 久久精品国产亚洲av涩爱 | 亚洲va在线va天堂va国产| 美女被艹到高潮喷水动态| 欧美日韩在线观看h| 久久韩国三级中文字幕| 成人精品一区二区免费| 草草在线视频免费看| 久久国内精品自在自线图片| 国产成人freesex在线 | 中文资源天堂在线| av免费在线看不卡| 亚洲一区高清亚洲精品| 精品一区二区三区视频在线观看免费| 深爱激情五月婷婷| 国产精品一区二区免费欧美| 亚洲精品一区av在线观看| 国产精品爽爽va在线观看网站| 日韩高清综合在线| 亚洲一区高清亚洲精品| 亚洲图色成人| 在线播放无遮挡| 精品人妻偷拍中文字幕| 美女黄网站色视频| av卡一久久| 极品教师在线视频| 熟妇人妻久久中文字幕3abv| 欧美日本亚洲视频在线播放| 精品久久久久久久末码| 亚洲欧美成人精品一区二区| 美女黄网站色视频| 97超级碰碰碰精品色视频在线观看| 亚洲色图av天堂| 国产成年人精品一区二区| 在线看三级毛片| 一级黄色大片毛片| 深爱激情五月婷婷| 真实男女啪啪啪动态图| 看非洲黑人一级黄片| 日本一二三区视频观看| 欧美绝顶高潮抽搐喷水| 成年女人永久免费观看视频| 精品午夜福利视频在线观看一区| 97碰自拍视频| 国产精品久久久久久av不卡| 日韩在线高清观看一区二区三区| 日韩欧美三级三区| 午夜福利成人在线免费观看| 亚洲精品日韩在线中文字幕 | 三级男女做爰猛烈吃奶摸视频| 国产爱豆传媒在线观看| 午夜免费男女啪啪视频观看 | 舔av片在线| 精品人妻熟女av久视频| 看黄色毛片网站| 国产av在哪里看| 一级毛片电影观看 | 身体一侧抽搐| 国产精品三级大全| 国产黄色视频一区二区在线观看 | 91精品国产九色| 欧美三级亚洲精品| 搡老妇女老女人老熟妇| 18+在线观看网站| 久久99热这里只有精品18| 中文字幕精品亚洲无线码一区| 国产毛片a区久久久久| 欧美精品国产亚洲| 99久久成人亚洲精品观看| 午夜福利在线在线| 好男人在线观看高清免费视频| 不卡视频在线观看欧美| 久久久久久大精品| 又爽又黄a免费视频| 自拍偷自拍亚洲精品老妇| 日本一二三区视频观看| 国内精品一区二区在线观看| 俄罗斯特黄特色一大片| 天堂av国产一区二区熟女人妻| 久久精品夜夜夜夜夜久久蜜豆| 别揉我奶头~嗯~啊~动态视频| 亚洲av五月六月丁香网| 国产精品日韩av在线免费观看| 欧美国产日韩亚洲一区| 亚洲精品日韩在线中文字幕 | 国产大屁股一区二区在线视频| 人人妻人人澡欧美一区二区| 美女cb高潮喷水在线观看| 91在线观看av| av免费在线看不卡| 日本三级黄在线观看| 日韩一本色道免费dvd| 日本爱情动作片www.在线观看 | 国产精品一区二区三区四区免费观看 | 十八禁国产超污无遮挡网站| 日韩成人伦理影院| 你懂的网址亚洲精品在线观看 | 亚洲欧美日韩高清在线视频| .国产精品久久| 国产午夜精品久久久久久一区二区三区 | 在线免费观看的www视频| 深爱激情五月婷婷| 午夜激情福利司机影院| 国产激情偷乱视频一区二区| 免费看a级黄色片| av视频在线观看入口| 特大巨黑吊av在线直播| 亚洲经典国产精华液单| 亚洲国产欧洲综合997久久,| 亚洲精品国产av成人精品 | 日韩欧美一区二区三区在线观看| 久久午夜福利片| 国内久久婷婷六月综合欲色啪| 成人亚洲欧美一区二区av| www.色视频.com| 麻豆国产av国片精品| 一级毛片aaaaaa免费看小| 老熟妇仑乱视频hdxx| 天堂√8在线中文| 国产淫片久久久久久久久| 日韩大尺度精品在线看网址| 日本黄大片高清| 欧美精品国产亚洲| 毛片女人毛片| 男女那种视频在线观看| 1000部很黄的大片| 免费高清视频大片| 别揉我奶头~嗯~啊~动态视频| 久久久欧美国产精品| 深夜a级毛片| 亚洲五月天丁香| 亚洲图色成人| 熟女电影av网| 精品乱码久久久久久99久播| 亚洲精品国产av成人精品 | 日日啪夜夜撸| 久久精品综合一区二区三区| 国产片特级美女逼逼视频| 国产色婷婷99| ponron亚洲| 成人午夜高清在线视频| 亚洲精品乱码久久久v下载方式| 亚洲人成网站在线播放欧美日韩| 国产一区二区亚洲精品在线观看| 在线看三级毛片| 国产精品乱码一区二三区的特点| 亚州av有码| 中文字幕免费在线视频6| 2021天堂中文幕一二区在线观| 好男人在线观看高清免费视频| 三级男女做爰猛烈吃奶摸视频| 欧美日韩乱码在线| 久久久久免费精品人妻一区二区| 精品久久久久久久久av| 国产色爽女视频免费观看| 一级a爱片免费观看的视频| 麻豆成人午夜福利视频| 亚洲第一区二区三区不卡| 99久久无色码亚洲精品果冻| 大香蕉久久网| 欧美性猛交╳xxx乱大交人| 啦啦啦韩国在线观看视频| 男女做爰动态图高潮gif福利片| 日本撒尿小便嘘嘘汇集6| 国产爱豆传媒在线观看| 午夜福利视频1000在线观看| 国产视频一区二区在线看| 久久韩国三级中文字幕| 又黄又爽又免费观看的视频| 听说在线观看完整版免费高清| 免费人成在线观看视频色| 日韩精品青青久久久久久| 成年女人永久免费观看视频| 99久久中文字幕三级久久日本| 午夜精品在线福利| 黄色欧美视频在线观看| 91久久精品电影网| 久久精品国产清高在天天线| 成人午夜高清在线视频| 一卡2卡三卡四卡精品乱码亚洲| 少妇熟女aⅴ在线视频| 美女黄网站色视频| 精品熟女少妇av免费看| 久久精品综合一区二区三区| 特大巨黑吊av在线直播| 日本黄色视频三级网站网址| 深爱激情五月婷婷| 最近最新中文字幕大全电影3| 亚洲真实伦在线观看| 春色校园在线视频观看| 亚洲无线观看免费| 色吧在线观看| 99热这里只有是精品在线观看| 亚洲中文字幕日韩| 俄罗斯特黄特色一大片| 国产成人a区在线观看| 午夜影院日韩av| 日本欧美国产在线视频| 看免费成人av毛片| 精品久久久久久久久av| 国产av一区在线观看免费| 久久久午夜欧美精品| 日韩高清综合在线| 欧美高清成人免费视频www| 国产精品无大码| 亚洲欧美中文字幕日韩二区| 欧美激情国产日韩精品一区| 99久久精品热视频| 日韩亚洲欧美综合| av在线亚洲专区| 久久婷婷人人爽人人干人人爱| 亚洲欧美日韩高清专用| 午夜视频国产福利| 自拍偷自拍亚洲精品老妇| 天天躁日日操中文字幕| 国产大屁股一区二区在线视频| 亚洲精品在线观看二区| 久久天躁狠狠躁夜夜2o2o| 天堂av国产一区二区熟女人妻| 日韩中字成人| 国产片特级美女逼逼视频| 久久久久国产网址| 亚州av有码| 欧美国产日韩亚洲一区| 亚洲一级一片aⅴ在线观看| 久久久久精品国产欧美久久久| 九九久久精品国产亚洲av麻豆| 欧美成人精品欧美一级黄| 日韩欧美精品v在线| 成人二区视频| 日本色播在线视频| 亚洲av不卡在线观看| 国产不卡一卡二| 久久精品国产99精品国产亚洲性色| 深夜a级毛片| 韩国av在线不卡| 亚洲精品亚洲一区二区| 夜夜夜夜夜久久久久| 午夜福利在线在线| 亚洲一区高清亚洲精品| avwww免费| 亚洲av不卡在线观看| 久久亚洲精品不卡| 色av中文字幕| 国产伦精品一区二区三区视频9| 亚洲第一电影网av| 精品乱码久久久久久99久播| 99精品在免费线老司机午夜| 欧美一区二区国产精品久久精品| 91在线观看av| 日韩成人av中文字幕在线观看 | 91av网一区二区| 亚洲精品456在线播放app| 午夜影院日韩av| 蜜桃亚洲精品一区二区三区| 久久国产乱子免费精品| 色尼玛亚洲综合影院| 国产高清激情床上av| 九九爱精品视频在线观看| 久久久久久久久大av| 国产又黄又爽又无遮挡在线| 亚洲内射少妇av| 可以在线观看毛片的网站| 床上黄色一级片| 成人精品一区二区免费| 欧美一区二区亚洲| 日韩精品中文字幕看吧| 99久久无色码亚洲精品果冻| 欧美三级亚洲精品| 俺也久久电影网| 麻豆久久精品国产亚洲av| 成人性生交大片免费视频hd| 国产午夜精品久久久久久一区二区三区 | 午夜视频国产福利| 亚洲性夜色夜夜综合| 免费看光身美女| 免费人成视频x8x8入口观看| 欧美日韩综合久久久久久| 一本久久中文字幕| 国产高清视频在线播放一区| 最近2019中文字幕mv第一页| 2021天堂中文幕一二区在线观| 如何舔出高潮| 免费av毛片视频| 国产色婷婷99| 淫秽高清视频在线观看| 国产探花极品一区二区| 99国产精品一区二区蜜桃av| 亚洲电影在线观看av| 国内精品宾馆在线| 日韩一本色道免费dvd| 国产69精品久久久久777片| 国产精品一区二区性色av| 给我免费播放毛片高清在线观看| 精品人妻偷拍中文字幕| 97超级碰碰碰精品色视频在线观看| 午夜福利18| 内地一区二区视频在线| 丰满的人妻完整版| 大又大粗又爽又黄少妇毛片口| 日韩强制内射视频| 搡老熟女国产l中国老女人| a级毛片免费高清观看在线播放| 国产伦在线观看视频一区| 免费观看人在逋| 欧美高清成人免费视频www| 久久综合国产亚洲精品| av天堂中文字幕网| 久久久国产成人免费| 国产精品综合久久久久久久免费| 免费在线观看成人毛片| 人人妻人人澡欧美一区二区| 午夜精品国产一区二区电影 | 中国国产av一级| 内射极品少妇av片p| 精品免费久久久久久久清纯| 欧美日韩综合久久久久久| 亚洲欧美日韩高清专用| 欧美又色又爽又黄视频| 成人鲁丝片一二三区免费| 日韩精品有码人妻一区| 久久久久久久久久久丰满| 男人舔女人下体高潮全视频| 国产高清三级在线| 亚洲精品国产成人久久av| 欧美潮喷喷水| 观看美女的网站| 亚洲色图av天堂| 男人的好看免费观看在线视频| 三级国产精品欧美在线观看| aaaaa片日本免费| 搡老岳熟女国产| 99久久成人亚洲精品观看| 精品久久久久久久久av| 亚洲,欧美,日韩| 91久久精品国产一区二区成人| 中文亚洲av片在线观看爽| 国产真实乱freesex| 婷婷精品国产亚洲av在线| 国产v大片淫在线免费观看| 亚洲av.av天堂| 国产色婷婷99| 乱人视频在线观看| 日本成人三级电影网站| 国产成人aa在线观看| 国产午夜精品久久久久久一区二区三区 | 91狼人影院| 欧美成人a在线观看| 国产成人精品久久久久久| 国产成人aa在线观看| 久久国产乱子免费精品| 精品久久久久久久久久免费视频| 亚洲内射少妇av| 成人永久免费在线观看视频| 国产av不卡久久| 成人永久免费在线观看视频| 欧美xxxx黑人xx丫x性爽| 中文亚洲av片在线观看爽| 美女内射精品一级片tv| 国产白丝娇喘喷水9色精品| avwww免费| 男女之事视频高清在线观看| 日日摸夜夜添夜夜添小说| 国产精品av视频在线免费观看| 欧美另类亚洲清纯唯美| 亚洲成人精品中文字幕电影| 国产69精品久久久久777片| 波多野结衣高清无吗| 麻豆成人午夜福利视频| 国内精品美女久久久久久| 久久国内精品自在自线图片| 免费av不卡在线播放| 久久久久国内视频| 在线a可以看的网站| av卡一久久| 婷婷精品国产亚洲av| 亚洲七黄色美女视频| 国产成人一区二区在线| 欧美性感艳星| 欧美人与善性xxx| 在线观看美女被高潮喷水网站| 欧美人与善性xxx| 综合色丁香网| 色5月婷婷丁香| 少妇裸体淫交视频免费看高清| 国产亚洲精品av在线| 狂野欧美激情性xxxx在线观看| 麻豆一二三区av精品| 18禁在线播放成人免费| 国产精品亚洲美女久久久| 少妇裸体淫交视频免费看高清| 精品少妇黑人巨大在线播放 | 国产成人freesex在线 | 人妻制服诱惑在线中文字幕| 露出奶头的视频| 丝袜美腿在线中文| 国产精品乱码一区二三区的特点| 听说在线观看完整版免费高清| 亚洲三级黄色毛片| 欧美日本亚洲视频在线播放| 午夜精品国产一区二区电影 | 成人欧美大片| 成人特级av手机在线观看| 成人永久免费在线观看视频| av在线天堂中文字幕| 伦精品一区二区三区| 一区二区三区四区激情视频 | 亚洲人与动物交配视频| 国产精品综合久久久久久久免费| 欧美色视频一区免费| 日日啪夜夜撸| 成人亚洲精品av一区二区| 国产高清激情床上av| 久久人妻av系列| 日韩欧美三级三区| 小蜜桃在线观看免费完整版高清| 免费观看人在逋| 白带黄色成豆腐渣| 最近手机中文字幕大全| 欧美最新免费一区二区三区| 春色校园在线视频观看| 久久欧美精品欧美久久欧美| 麻豆精品久久久久久蜜桃| 精品久久久久久久久亚洲| 精品久久久久久成人av| www.色视频.com| 美女被艹到高潮喷水动态| 国产精品女同一区二区软件| 一个人看视频在线观看www免费| 偷拍熟女少妇极品色| 亚洲av五月六月丁香网| 久久久久国内视频| 亚洲欧美日韩东京热| av在线播放精品| 日韩精品中文字幕看吧| 在线观看午夜福利视频| 三级经典国产精品| 国产亚洲av嫩草精品影院| 成人特级黄色片久久久久久久| 51国产日韩欧美| 搡女人真爽免费视频火全软件 | 国产爱豆传媒在线观看| 蜜桃亚洲精品一区二区三区| 国内揄拍国产精品人妻在线| 亚洲人成网站高清观看| 床上黄色一级片| 亚洲欧美成人精品一区二区| 最近中文字幕高清免费大全6| 亚洲成人av在线免费| 国产淫片久久久久久久久| 国产男靠女视频免费网站| 精品日产1卡2卡| 日韩精品有码人妻一区| 中文字幕免费在线视频6| 香蕉av资源在线| 亚洲人成网站高清观看| 亚洲内射少妇av| 97超碰精品成人国产| 一级毛片久久久久久久久女| 亚洲av二区三区四区| 国内精品宾馆在线| 午夜福利高清视频| 欧美丝袜亚洲另类| 神马国产精品三级电影在线观看| 性欧美人与动物交配| 高清日韩中文字幕在线| 久久久精品大字幕|